MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14740338.2024.2396396

Медицинская библиотека · Expert opinion on drug safety · 2024

Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review.

Solmi Marco, Miola Alessandro, Capone Federico, Pallottino Simone, Højlund Mikkel, Firth Joseph, Siskind Dan, Holt Richard I G, Corbeil Olivier, Cortese Samuele, Dragioti Elena, Du Rietz Ebba, Nielsen René Ernst, Nordentoft Merete, Fusar-Poli Paolo, Hartman Catharina A, Høye Anne, Koyanagi Ai, Larsson Henrik, Lehto Kelli, Lindgren Peter, Manchia Mirko, Skonieczna-Żydecka Karolina, Stubbs Brendon, Vancampfort Davy, Vieta Eduard, Taipale Heidi, Correll Christoph U, ECNP Physical And meNtal Health Thematic Working Group (PAN-Health)

СтатьяОбзорПеревод в очереди

Аннотация

INTRODUCTION

People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.

AREAS COVERED: We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.

EXPERT OPINION: To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.

Для цитирования: Solmi Marco, Miola Alessandro, Capone Federico, Pallottino Simone, Højlund Mikkel, Firth Joseph, Siskind Dan, Holt Richard I G, Corbeil Olivier, Cortese Samuele, Dragioti Elena, Du Rietz Ebba, Nielsen René Ernst, Nordentoft Merete, Fusar-Poli Paolo, Hartman Catharina A, Høye Anne, Koyanagi Ai, Larsson Henrik, Lehto Kelli, Lindgren Peter, Manchia Mirko, Skonieczna-Żydecka Karolina, Stubbs Brendon, Vancampfort Davy, Vieta Eduard, Taipale Heidi, Correll Christoph U, ECNP Physical And meNtal Health Thematic Working Group (PAN-Health). Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review.. Expert opinion on drug safety. 2024. DOI: 10.1080/14740338.2024.2396396.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.